Evolus (EOLS) Expected to Announce Quarterly Earnings on Tuesday

Evolus (NASDAQ:EOLS) is expected to be announcing its earnings results after the market closes on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $79.01 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Evolus Stock Performance

Evolus stock opened at $14.11 on Tuesday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market capitalization of $893.46 million, a PE ratio of -15.51 and a beta of 1.33. The company has a 50 day moving average price of $12.40 and a 200-day moving average price of $14.05. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82.

Analysts Set New Price Targets

A number of research analysts have commented on EOLS shares. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Friday, February 14th. Barclays lifted their price objective on shares of Evolus from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, January 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Tuesday, January 21st.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.